RecruitingPhase 1NCT05652335
Cardiovascular
Light Chain Amyloidosis
Also known as AL amyloidosis, primary amyloidosis, immunoglobulin light-chain amyloidosis
Light Chain Amyloidosis is caused by a clonal population of plasma cells in the bone marrow producing misfolded immunoglobulin light chains that aggregate into amyloid fibrils and deposit in vital organs, most critically the heart and kidne
ORPHA:85443 ↗Prevalence Approximately 8–12 per million per yearOnset Adulthood; median diagnosis in the sixth decadeAcquired (clonal plasma cell disorder)
54
studies recruiting now
as of 7 Sept 2026
295
studies registered in total
as of 7 Sept 2026
11
countries with a recruiting site
as of 7 Sept 2026
10 Jun 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT06569147
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RecruitingPhase 1 / Phase 2NCT05145816
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RecruitingPhase 1 / Phase 2NCT06292780
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
RecruitingPhase 2NCT07638683
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 54 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Light Chain Amyloidosis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: Amyloidosis Foundation Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Light Chain Amyloidosis
Light Chain Amyloidosis is caused by a clonal population of plasma cells in the bone marrow producing misfolded immunoglobulin light chains that aggregate into amyloid fibrils and deposit in vital organs, most critically the heart and kidneys. Unlike hereditary amyloidosis, AL is not inherited but arises de novo and is closely related to multiple myeloma, requiring haematological treatment directed at the underlying plasma cell clone. Cardiac involvement, present in up to 70% of patients at diagnosis, is the primary determinant of prognosis and drives treatment urgency; the introduction of daratumumab-based combination regimens has markedly improved haematological response rates and cardiac outcomes.
Common clinical features
Heart failure with preserved or reduced ejection fractionPeriorbital purpura (raccoon eyes) pathognomonic but uncommonMacroglossiaNephrotic-range proteinuria and progressive renal impairmentPeripheral neuropathy and carpal tunnel syndromeOrthostatic hypotension due to autonomic neuropathyFatigue, weight loss, and early satietyElevated NT-proBNP disproportionate to degree of overt heart failure
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
2 approved treatments and 21 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tafamidis (Vyndamax)Approved: Tafamidis Meglumine (Vyndaqel)
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 3Dexamethasone (Aeroseb-dex)
Phase 3Lenalidomide (Lenalidomide accord)
Phase 3Daratumumab (Daratumumab component of darzalex faspro)
Phase 3Anselamimab
Phase 3Birtamimab
Phase 2/3Doxycycline (Doxirobe)
Phase 2Amiodarone Hydrochloride (Amidox)
+ 13 more in development
Before you apply
Things trial teams commonly ask about for Light Chain Amyloidosis. Not eligibility rules; those are set by each study.
- Confirmation of AL amyloidosis requires both demonstration of amyloid deposits (Congo red biopsy) and proof of a clonal plasma cell disorder (serum/urine protein electrophoresis, free light chain assay, bone marrow biopsy); all results are required for trial screening.
- Cardiac staging (Mayo 2004 or 2012 criteria using NT-proBNP and troponin) is used to stratify eligibility; Stage IIIb/IV patients may be excluded from some trials due to safety concerns.
- Prior haematological treatment lines and response status affect eligibility for relapsed/refractory trials; a detailed treatment history including cycle counts and best responses is essential.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).